Analysis File of Drug-Induced Lung Injury - Expert Opinion for Analysis of Big Data (Aug 23, 2024)_(9819734452)_(Springer)

This book describes the pathologic conditions of drug-induced lung injuries, monitoring strategies, and guides on how to interpret the evidence. It also dives into particular drugs that caused the disorder, such as EGFR inhibitors, anti-EGFR antibodies, mTOR inhibitors, proteasome inhibitors, immune checkpoint inhibitors, neoangiogenesis inhibitors, and other molecular targeted drugs. It outlines the analysis and interpretation of the post-marketing survey on surveillance of each drug for inducing pulmonary lesions presenting diffuse haziness. The data and analysis from this survey are valuable since a guideline is yet to be established due to limited clinical evidence and cases. As new drugs are developed, establishing treatment and event management is crucial. Thus, Drug-induced Pulmonary Disorder in Medical Oncology - Expert Opinion to Decipher Big Data summarizes the accumulated information to provide a foundation for further research advancement. The book offers a refreshing alternative to current approaches to medical oncology and respiratory diseases professionals and will also attract medical affairs members in global pharmaceutical companies. Preface Overview: Experience of Drug-Induced Lung Injury Exploratory Committee Contents About the Author Part I: Understanding Drug-Induced Lung Injuries Chapter 1: Understanding Drug-Induced Lung Injuries 1.1 Pathologic Conditions of Drug-Induced Lung Injuries and Factors Inferred from Big Data 1.1.1 Mechanism of Onset 1.1.2 Pathologic Conditions 1.1.3 Treatments 1.1.4 Factors Inferred from Big Data 1.1.4.1 Factor 1: Drug 1.1.4.2 Factor 2: Personal Genetic Predisposition 1.1.4.3 Factor 3: Personal Risk Factors and Organs’ Conditions 1.2 Practice of the Monitoring 1.2.1 EGFR Tyrosine Kinase Inhibitors (EGFR-TKI) 1.2.2 mTOR inhibitors and Immune Checkpoint Inhibitors 1.2.3 Cases with Risk Factors and Prognosis Factors 1.3 Cautions in Interpreting the Big Data Evidence 1.3.1 Consideration of the Lung Damage 1.3.2 Specificity of the First-in-Class Drug 1.3.3 Pulmonary Thromboembolism as Differential Diagnoses 1.3.4 Conforming Parameters References Part II: Actual Practice in Drug-Induced Lung Injuries of Each Drug Chapter 2: EGFR Inhibitors (Gefitinib, Erlotinib, Afatinib, and Osimertinib) 2.1 Gefitinib (Iressa) 2.1.1 An in-Cohort Case-Controlled Study in Patients with Lung Cancer as Subjects (Fig. 2.1) Results Topic 2.1.2 Findings from the Surveys Topic Topic Inside Story Inside Story 2.2 Erlotinib (Tarceva) 2.2.1 Post-Marketing all-Case Survey in Patients with Non-small Cell Lung Cancer Topic 2.2.2 Findings from the Survey Topic Topic 2.2.3 Specific Survey of Use Achievement in Patients with Pancreatic Cancer (All-Case Survey) (Fig. 2.7) 2.2.4 Findings from the Survey Topic Supplementary Note Image Analysis Results 2.2.5 Findings from the Survey Topic 2.3 Afatinib (Gilotrif) 2.3.1 Post-Marketing All-Case Survey in Subjects with Non-small Cell Lung Cancer 2.3.2 Findings from the Survey Topic 2.4 Osimertinib (Tagrisso) (Fig. 2.8) 2.4.1 Post-Marketing All-Case Survey in Subjects with Non-small Cell Lung Cancer 2.4.2 Findings from the Survey Topic Topic 2.5 Vandetanib (Caprelsa) References Chapter 3: Anti-EGFR Antibodies (Cetuximab, Panitumumab, and Necitumumab) 3.1 Cetuximab (Erbitux) (Fig. 3.1) 3.1.1 Post-Marketing All-Case Survey in Colon and Rectal Cancers (Fig. 3.1) 3.1.1.1 Results 3.1.2 Findings from the Survey 3.1.2.1 Topic 3.2 Panitumumab (Vectibix) [5–10] 3.2.1 Post-Marketing All-Case Survey in Patients with Colon and Rectal Cancers 3.2.2 Findings from the Survey 3.2.2.1 Topic 3.3 Necitumumab (Portrazza) [11] 3.3.1 Post-Marketing Survey in Patients with Squamous Cell Lung Cancer References Chapter 4: mTOR Inhibitors (Temsirolimus and Everolimus) 4.1 Temsirolimus (Torisel) 4.2 Everolimus (Afinitor) 4.2.1 Post-Marketing All-Case Survey in Patients with Renal Cell Cancer 4.2.2 Findings from the Surveys 4.2.2.1 Topic 4.2.2.2 Inside Story 4.2.2.3 Topic 4.2.2.4 Topic References Chapter 5: Proteasome Inhibitor (Bortezomib) 5.1 Bortezomib (Velcade) 5.1.1 Topic 5.1.1.1 Post-Marketing All-Case Survey in Subjects with Multiple Myeloma 5.1.1.2 Analyses of the Image Findings in Cases of Lung Injuries by Expert meetings [4] 5.1.2 Findings from the Survey 5.1.2.1 Topic 5.1.2.2 Inside Story References Chapter 6: Immune Checkpoint Inhibitors (Nivolumab, Pembrolizumab, Atezolizumab, and Durvalumab) 6.1 Nivolumab (Opdivo) (Fig. 6.1) 6.1.1 All-Case Survey in Subjects with Non-small Cell Lung Cancer 6.1.2 Findings from the Surveys 6.1.2.1 Topic 6.2 Pembrolizumab (Keytruda) (Fig. 6.6) 6.2.1 Usage-Achievement Surveys in Subjects with Malignant Melanoma and Non-small Cell Lung Cancer 6.2.2 Findings from the Surveys 6.3 Atezolizumab (Tecentriq) 6.3.1 Early Post-Marketing Surveys in Subjects with Non-small Cell Lung Cancer 6.4 Durvalumab (Imfinzi) 6.4.1 Topic References Chapter 7: Neoangiogenesis Inhibitors (Sunitinib, Sorafenib, and Bevacizumab) 7.1 Sunitinib (Sutent) 7.1.1 Post-Marketing All-Case Survey in Subjects with Renal Cell Cancer 7.1.2 Findings from the Surveys 7.2 Sorafenib (Nexavar) 7.2.1 Post-Marketing All-Case Survey in Subjects with Renal Cell Cancer 7.2.2 Post-Marketing All-Case Survey in Subjects with Renal Cell Cancer/Hepatic Cell Cancer 7.2.3 Findings from the Surveys 7.3 Bevacizumab (Avastin) [5] 7.3.1 Post-Marketing All-Case Survey in Subjects with Colon/Rectal Cancers 7.3.2 Findings from the Surveys References Chapter 8: Other Molecular-Targeted Drugs (Crizotinib, Alectinib, Etc.) 8.1 Crizotinib (Xalkori) 8.1.1 Post-Marketing All-Case Survey in Subjects with Non-small Cell Lung Cancer 8.1.2 Findings from the Surveys 8.1.2.1 Inside Story 8.2 Alectinib (Alecensa) [3, 4] 8.2.1 Post-Marketing All-Case Survey in Subjects with Non-small Cell Lung Cancer (Fig. 8.3) 8.2.2 Findings from the Surveys 8.3 Trastuzumab (Herceptin) 8.4 Pertuzumab (Perjeta) 8.5 Palbociclib (Ibrance) References Chapter 9: Antibody-Drug Conjugates (ADC) (Trastuzumab Emtansine and Trastuzumab Deruxtecan) 9.1 Trastuzumab Emtansine (T-DM1, Kadcyla) [1, 2] 9.2 Trastuzumab Deruxtecan (Enhertu) (Fig. 9.3) [3] 9.2.1 Clinical Study (Partially Revised from Reference [3]) 9.2.1.1 Study U201 Results 9.2.1.2 Study J202 Results 9.2.1.3 Analysis Results of the Initial Doses and Cancer Types Results 9.2.2 Findings from the Surveys 9.2.2.1 Topics References Chapter 10: Anticancer Drugs (TS-1, Taxanes, CPT-11, Platinum-Containing Drugs, Etc.) 10.1 Bleomycin (Bleo) (Fig. 10.1) 10.1.1 Findings from the Surveys 10.2 CPT-11 (Topotecin, Campto) (Fig. 10.3) 10.2.1 Post-Marketing Appearance of Side Effects of Interstitial Lung Diseases 10.2.2 Findings from the Surveys 10.3 Tegafur/Gimeracil/Oteracil Potassium Combination Drugs (TS-1) (Fig. 10.5) 10.3.1 Achievement Surveys for Lung Cancer/Other cancers [6] 10.3.2 Findings from the Surveys 10.4 Platinum-Containing Drugs: Oxaliplatin (Elplat) 10.4.1 Achievement Surveys for the Usage [7] 10.5 Platinum-Containing Drugs: Miriplatin (Miripla) 10.5.1 Investigation by the Evaluation Committee of a Third Party 10.5.2 Findings from the Surveys 10.6 Pemetrexed (Alimta) 10.6.1 Findings from the Surveys 10.7 Amrubicin (Calsed) 10.8 Gemcitabine (Gemzar) 10.8.1 Single-Facility Consecutive Surveys 10.8.2 Findings from the Surveys References Index